Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis

Light chain (AL) amyloidosis is a plasma cell neoplasm associated with insoluble fibril deposition from clonal immunoglobulin chains systemically. The disease is associated with high early mortality and morbidity owing to advanced organ deposition as well as lack of proven de-fibrillogenic therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Souza, Anita, Flynn, Kathryn, Chhabra, Saurabh, Dhakal, Binod, Hamadani, Mehdi, Jacobsen, Kirsten, Pasquini, Marcelo, Weihrauch, Dorothee, Hari, Parameswaran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898504/
https://www.ncbi.nlm.nih.gov/pubmed/29696194
http://dx.doi.org/10.1016/j.conctc.2017.08.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898504/
https://www.ncbi.nlm.nih.gov/pubmed/29696194
http://dx.doi.org/10.1016/j.conctc.2017.08.012

Ejemplares similares